[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100594320":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":35,"responsibleParty":55,"collaborators":10,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":10,"eligibilityCriteria":63,"healthyVolunteers":59,"sex":64,"minAge":65,"maxAge":10,"enrollmentInfo":66,"targetDuration":69,"studyType":70,"phases":10,"briefSummary":71,"conditions":72,"keywords":75,"overallStatus":38,"whyStopped":10,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"THYROSCOPE INC.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Glandy HYPER Validation Cohort",null,"articipants diagnosed with Graves' disease who are either newly diagnosed or currently under treatment. All participants will wear a commercially available smartwatch (Apple or Samsung) to measure sleep heart rate, and undergo thyroid function testing (free T4 and TSH) at baseline and follow-up visits over 12 weeks. No therapeutic intervention will be applied, and data from wearable devices will be used solely for observational performance evaluation of the investigational software.",[13],"Device: Heart rate-based AI software for detecting thyrotoxicosis",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DEVICE","Heart rate-based AI software for detecting thyrotoxicosis","A software-based investigational medical device that uses artificial intelligence to detect the thyrotoxic state in patients with hyperthyroidism. The device analyzes resting heart rate data collected from wearable devices along with thyroid function test results (free T4 and TSH). The device is not FDA-approved and will be used solely for observational performance evaluation without influencing clinical care.",[9],[21],{"name":22,"affiliation":23,"role":24},"Umeshi Masharani, MD","University of California, San Francisco","PRINCIPAL_INVESTIGATOR",[26,31],{"name":27,"role":28,"phone":29,"phoneExt":10,"email":30},"Jun An","CONTACT","‭+82 10-2849-0041‬","jun.an@thyroscope.com",{"name":32,"role":28,"phone":33,"phoneExt":10,"email":34},"Jae Hoon Moon, MD, PhD","+82-10-5105-9815","jaehoon.moon@thyroscope.com",[36],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Umesh Masharani","RECRUITING","San Francisco","California","94143","United States","US",{"type":45,"coordinates":46},"Point",[47,48],-122.41942,37.77493,{"lat":48,"lon":47},[51],{"name":52,"role":28,"phone":53,"phoneExt":10,"email":54},"Umesh Masharani, MD","415-353-2350","Umesh.Masharani@ucsf.edu",{"type":56,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100594320","evaluating-an-ai-tool-for-detecting-thyrotoxic-states-100594320",false,"NCT07017907","Evaluating an AI Tool for Detecting Thyrotoxic States","Performance Evaluation of the Software Medical Device to Detect the Thyrotoxic State in Patients With Hyperthyroidism","Inclusion Criteria:\n\n* Adults aged 22 years or older, regardless of sex.\n* Individuals who are newly diagnosed with Graves' disease or currently undergoing treatment for it.\n* Individuals who have received sufficient explanation about the investigational software and are able to use it appropriately.\n* Individuals who voluntarily agree to participate in the study and have signed informed consent, either directly or via a legally authorized representative.\n\nExclusion Criteria:\n\n* Individuals with cardiac conditions such as arrhythmia or heart failure.\n* Individuals taking medications that significantly affect heart rate, including antiarrhythmics or antihistamines. (Intermittent short-acting beta-blockers are allowed.)\n* Pregnant or breastfeeding individuals, or those planning pregnancy during the study period or not using appropriate contraception.\n* Individuals with significant comorbidities that interfere with follow-up or study compliance.\n* Individuals with severe psychiatric disorders, substance use disorder, or alcohol dependence.\n* Individuals deemed ineligible at the discretion of the investigator for safety or ethical concerns.","ALL","22 Years",{"count":67,"type":68},15,"ESTIMATED","12 Weeks","OBSERVATIONAL","This observational study aims to evaluate the performance of a software-based medical device, Glandy HYPER, in detecting the thyrotoxic state in patients with hyperthyroidism. The device utilizes heart rate data collected from commercially available wearable devices and compares it with thyroid function test results. The study will enroll patients diagnosed with Graves' disease, monitoring their heart rate during sleep and correlating these measurements with free T4 levels obtained through serial blood testing. No investigational device output will be disclosed to participants, and the study will not alter standard clinical care.",[73,74],"Graves Disease","Hyperthyroidism\u002FThyrotoxicosis",[76,77,78,79,80,81,82],"Graves disease","Hyperthyroidism","Thyrotoxicosis","Artificial intelligence","Heart rate","SaMD","wearable device","2026-05-28",{"date":85,"type":86},"2026-06-01","ACTUAL",{"date":88,"type":86},"2026-01-09",{"date":90,"type":68},"2026-12-31",{"name":5,"class":6},1]